[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345871-105":59,"doc-detail-345871-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","from-antibody-drugs-to-rna-interference-and-nanotherapy-the-evolution-and-integration-of-targeted-strategies-in-gastric-cancer-review","From Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer - Review","","Gastric cancer is a leading cause of cancer death worldwide, with many patients diagnosed at advanced stages and poor five-year survival. Targeted therapy is shifting toward precise gene regulation rather than solely blocking signaling pathways. This review synthesizes antibody-based targeted drugs, RNA interference approaches, and nanocarrier delivery systems, explaining how biomarkers can improve survival while resistance and low response rates constrain current treatments. It also details how RNAi silences oncogenic drivers and can remodel the immunosuppressive tumor microenvironment, yet faces degradation, escape, off-target, and penetration limitations, and how nanocarriers address these barriers to enable controlled, tumor-triggered cargo release.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-antibody-drugs-to-rna-interference-and-nanotherapy-the-evolution-and-integration-of-targeted-strategies-in-gastric-cancer-review/345871/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-antibody-drugs-to-rna-interference-and-nanotherapy-the-evolution-and-integration-of-targeted-strategies-in-gastric-cancer-review/345871.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How do nanocarrier systems improve delivery of antibodies and siRNA?","Question",{"text":112,"@type":113},"Nanocarriers such as lipid nanoparticles and polymeric micelles protect siRNA from degradation, enhance cellular uptake, and enable controlled release. They can also penetrate dense tumor stroma and trigger cargo release in response to microenvironmental cues.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},345871,1790387829,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nFrom Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer  \nSonglin Wang 1 , *, Yinhong Dong 1 , *, Lan Ma 2–4 , *, Jiangfeng Wu2–4 , Daoguo Long 1 , Zhao Mei 5 , 6 , Chuanlin Jiang 1 , Xiaoguang Lyu 1 , 7  \n1Zhongxiang People’s Hospital, Zhongxiang, People’s Republic of China; 2Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, People’s Republic of China; 3College of Basic Medical Science, China Three Gorges University, Yichang, People’s Republic of China; 4Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, People’s Republic of China; 5Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University, Yichang, People’s Republic of China; 6Department of Pharmacy, Yichang Central People’s Hospital, Yichang, People’s Republic of China; 7Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Chuanlin Jiang; Xiaoguang Lyu, Email [13677265887@139.com](13677265887@139.com); [dawnlxg@whu.edu.cn](dawnlxg@whu.edu.cn)  \n\n| Abstract: Gastric cancer is a leading cause of cancer death worldwide. Targeted therapy is shifting from blocking signaling pathways to precise gene regulation. This review covers three key areas: antibody drugs, RNAi, and nanocarriers. Anti-HER2 agents, VEGFR2 inhibitors, Claudin 18.2-directed therapies and PD-1/PD-L1 inhibitors improve survival in biomarker-selected patients—but resistance and low response rates (ORR \u003C 20% in unselected groups) limit their use. RNAi silences key oncogenes to reverse chemoresistance and reprogram the immunosuppressive tumor microenvironment, but it suffers from rapid degradation, poor endosomal escape, offtarget effects, and weak tumor penetration. Nanocarrier systems—including lipid nanoparticles (LNPs), stimuli-responsive micelles, and mesoporous silica—combined with aptamers enable targeted delivery of therapeutic antibodies and siRNA, penetration across stromal barriers, and controlled, tumor microenvironment–triggered cargo release. Altogether, the future of gastric cancer therapy is moving beyond monotherapy to a five-part strategy: antibody targeting, RNA silencing, nanocarrier delivery, AI-guided decisions, and immune remodeling.\u003Cbr>Keywords: gastric cancer, target therapy, RNA interference, siRNA, shRNA, nanoparticles |\n| --- |\n| Gastric cancer remains a significant global health challenge—it is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide, with 684,000 lives lost in 2022 (GLOBOCAN) .1 In China, gastric cancer is the third in incidence and the second in mortality—accounting for 478,000 new cases and 373,000 deaths annually.2,3 Due to its asymptomatic nature in the early stage, 70% of patients are diagnosed at advanced stage, resulting in a five-year overall survival rate of less than 10% .4–7 These figures underscore an urgent need for more effective therapies to delay tumor progression and extend survival time.\u003Cbr>Antibody-based drugs launched targeted therapy for gastric cancer. Trastuzumab validated HER2, ramucirumab enabled anti-angiogenesis, and immune checkpoint inhibitors achieved durable responses in biomarker-selected patients.8–11 But resistance—due to target loss, pathway redundancy, or immune evasion—and low response rates in unselected patients remain key challenges. 10 RNA interference (RNAi) offers the capacity to silence pathogenic genes at the mRNA level.12 In gastric cancer, siRNAs directed against HER2, c-MET, or KRAS mutants have shown promising results in preclinical studies. 13 The translational barrier, however, is delivery: naked nucleic acids are rapidly degraded, poorly internalized, and prone to of","cbCaivP2deD65XJT","https://ap.wps.com/l/cbCaivP2deD65XJT","pdf",2626994,15,"English","# Abstract\n# Antibody-based targeted therapy in gastric cancer\n## Biomarker selection, response, and resistance\n# RNA interference (RNAi) for gene silencing\n## Therapeutic rationale and delivery barriers\n# Nanocarrier systems for targeted delivery\n## LNPs, micelles, and stimuli-responsive release\n# Integrated future strategy for treatment","[{\"question\":\"How do nanocarrier systems improve delivery of antibodies and siRNA?\",\"answer\":\"Nanocarriers such as lipid nanoparticles and polymeric micelles protect siRNA from degradation, enhance cellular uptake, and enable controlled release. They can also penetrate dense tumor stroma and trigger cargo release in response to microenvironmental cues.\"}]","From Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer - Review | PDF",1790059194,38,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b75d694ac5abc43997a32c0dbf0299a.webp",983,1272,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/125d4b7c771d5b20c5d624cf548cef78.webp",982,1270,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0cc5e8daa8f529ee92cc9af1fe90d8f.webp",981,757,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f8365faac94777b43eeb16dfc2656a2.webp",980,1268]